IP Library Granted Patent US 11,208,377
Granted Patent B2
US 11,208,377 · App. 16/103,607 · Granted Dec 28, 2021

3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof

Inventors: Christopher D. Hein (Costa Mesa, CA); Tien T. Duong (Rancho Santa Margarita, CA); Santosh Sinha (Ladera Ranch, CA); Ling Li (Irvine, CA); Jeremiah H. Nguyen (La Puente, CA); David W. Old (Irvine, CA); Robert Burk (Laguna Beach, CA); Veena Viswanath (Irvine, CA); Sandhya Rao (Irvine, CA); John E. Donello (Dana Point, CA)
Assignee: ALLERGAN, INC.
C07C311/39A61P17/06A61P27/02A61P29/00C07B59/00C07C211/52C07C237/44C07C311/43C07D215/42C07D307/36C07D307/79C07D333/54C07B2200/05C07C2601/02C07C2601/04C07C2601/08C07C2601/14C07C2601/18C07C2602/10C07C2602/12C07C2603/70C07C2603/97
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,208,377
App. No.
16/103,607
Granted
Dec 28, 2021
Kind
B2
Abstract

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.

Claims (18)

1. A compound of Formula I or a pharmaceutically acceptable salt thereof, including an enantiomer, a diastereoisomer, a tautomer thereof:

wherein

R 1 is

C 1-10 alkyl optionally substituted with at least one group selected from OR 6 , —CO 2 R 6 , and halo;

R 2 is hydrogen;

R 3 is

6 to 12 membered aryl optionally substituted with at least one group selected from C 1-6 alkyl, halo, and OR 6 ;

R 4 is —SO 2 NR 6 R 7 ;

R 5 is halo; and

R 6 and R 7 are independently selected from hydrogen and C 1-6 alkyl.

2. The compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein R 1 is C 1-10 alkyl substituted with at least one group selected from OR 6 , halo, and —CO 2 R 6 .

3. The compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein R 6 is hydrogen.

4. The compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the moiety:

is of the form:

5. The compound or a pharmaceutically acceptable salt thereof of any one of claim 1 , wherein the moiety:

is of the form:

6. The compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2018
From: HEIN, CHRISTOPHER D.; DUONG, TIEN T.; SINHA, SANTOSH; LI, LING; NGUYEN, JEREMIAH H.; OLD, DAVID W.; BURK, ROBERT; VISWANATH, VEENA; RAO, SANDYHA; DONELLO, JOHN E.
To: ALLERGAN, INC.
Reel/Frame 046653/0408 →
Continuity (2)
Provisional Application 62545331 · Aug 14, 2017
Related Publication 20190047947A1 · Feb 14, 2019